Adverse Effects of Oseltamivir in Pediatric Patients
Common Adverse Effects
- Vomiting is the most frequent adverse reaction, occurring in 16% of pediatric patients aged 1-12 years treated with oseltamivir versus 8% receiving placebo 1
- Nausea occurs in approximately 10% of treated patients 2
- Diarrhea is particularly notable in infants under 1 year of age, occurring in 7% of treated infants 2
- Administration with food may improve gastrointestinal tolerability 2
- Headache occurs in approximately 2% of treated pediatric patients 2
- Skin reactions including rash and diaper rash (7% in infants) are reported 2
Serious but Rare Adverse Effects
- Comprehensive reviews of controlled clinical trial data have failed to establish a causal link between oseltamivir and neurologic or psychiatric events 1, 3
- Influenza infection itself is strongly associated with neuropsychiatric symptoms, which may occur before oseltamivir initiation 4
- The FDA advises monitoring children closely for abnormal behavior during treatment, though the risk in patients taking oseltamivir is no higher than in those not receiving antivirals 4
- Anaphylactic/anaphylactoid reactions, though rare, can occur 2
Age-Specific Considerations
- Vomiting is the predominant adverse effect at 16% versus 8% in placebo in children 1-12 years 1
- The adverse effect profile is similar to adults, with nausea (10%), vomiting (8%), and headache (2%) being most common in adolescents (≥13 years) 2
Balance of Benefits vs. Harms
- The balance between benefits and harms should be considered, but current guidelines support that benefits outweigh risks in hospitalized, severely ill, or high-risk pediatric patients 1
Oseltamivir Side Effects and Management in Children
Introduction to Oseltamivir Side Effects
- The Centers for Disease Control and Prevention recommends taking oseltamivir with food to significantly reduce the severity of nausea and vomiting, improving tolerability without compromising efficacy 5, 6
Benefits of Oseltamivir Treatment
- Oseltamivir reduces illness duration by approximately 17.6-29.9 hours in otherwise healthy children, according to the Morbidity and Mortality Weekly Report 5
- It reduces the risk of otitis media by 34% in children, as reported by the Morbidity and Mortality Weekly Report 5
- Only approximately 1% of patients discontinued oseltamivir due to side effects in clinical trials, as noted in the Morbidity and Mortality Weekly Report and MMWR Recommendations and Reports 5, 6, 7